Claims for Patent: 10,048,258

Summary for Patent: 10,048,258

Title:	Oscillating immunoassay method and device
Abstract:	The present invention provides apparatus and methods for the rapid determination of analytes in liquid samples by immunoassays incorporating magnetic capture of beads on a sensor capable of being used in the point-of-care diagnostic field.
Inventor(s):	Miller; Cary James (Ottawa, CA), Campbell; John Lewis Emerson (Ottawa, CA)
Assignee:	Abbott Point of Care Inc. (Princeton, NJ)
Application Number:	15/086,340
Patent Claims:	1. A method of performing a sandwich immunoassay for an analyte, said method comprising: mixing magnetically susceptible beads with a sample containing an analyte, wherein the beads are coated with a first antibody to the analyte and a signaling moiety; oscillating the beads across the surface of a sensing electrode in an immunosensor coated with a second antibody to the analyte, thereby forming an antibody sandwich and immobilizing the beads on the immunosensor, wherein the sensing electrode is position in a conduit for receiving the sample containing the analyte mixed with the beads, wherein the conduit comprises two magnetic zones, and wherein the beads are oscillated in the direction of a capture motion of the beads; washing unbound sample and beads from the immunosensor; and detecting the signaling moiety immobilized on said immunosensor. 2. The method of claim 1, wherein the sample is selected from the group consisting of blood, plasma, serum, urine, interstitial fluid and cerebrospinal fluid. 3. The method of claim 1, wherein the sample is amended with an anticoagulant. 4. The method of claim 1, wherein the beads comprise ferrite. 5. The method of claim 1, wherein the beads comprise magnetite (Fe.sub.3O.sub.4). 6. The method of claim 1, wherein the beads comprise a magnetically susceptible core with a polymer coating. 7. The method of claim 1, wherein the beads have an average particle size of from 0.01 .mu.m to 20 .mu.m. 8. The method of claim 1, wherein the beads have an average particle size of from 0.1 .mu.m to 5 .mu.m. 9. The method of claim 1, wherein the beads have an average particle size of from 0.2 .mu.m to 1.5 .mu.m. 10. The method of claim 1, wherein the beads dissolve from a dry matrix into the sample. 11. The method of claim 1, wherein the signaling moiety dissolves from a dry matrix into the sample. 12. The method of claim 1, wherein the first and second antibody are to a low-abundance analyte in the sample. 13. The method of claim 1, wherein the first and second antibody are to an analyte selected from the group consisting of cardiac troponin I, troponin T, a troponin complex, human chorionic gonadotropin, BNP, creatine kinase, creatine kinase subunit M, creatine kinase subunit B, creatine kinase MB (CK-MB), proBNP, NT-proBNP, myoglobin, myosin light chain and modified fragments thereof. 14. The method of claim 1, wherein the first and second antibody are to an analyte selected from the group consisting of beta-HCG, TSH, ultra hTSH II, TT3, TT4, FT3, FT4, myeloperoxidase, D-dimer, CRP, NGAL, PSA, LH, FSH, prolactin, progesterone, estradiol, DHEA-S, AFP, CA 125 II, CA 125, CA 15-3, CA 19-9, CA 19-9XR, CEA, thyroxine (T4), triiodothyronine (T3), T-uptake, Tg, anti-Tg, anti-TPO, ferritin, cortisol, insulin, HBsAg, HCV Ag/Ab combo, HCV core Ag, anti-HCV, AUSAB (anti-HBs), CORE, CORE-M, SHBG, iPTH, theophylline, sirolimus, tacrolimus, anti-HAV, anti-HAV IgM, HAVAB, HAVAB-M, HAVAB-M2.0, HAVAB-G, HAVAB 2.0, HAVAB 2.0 Quant, IgM, CMV IgM, CMV IgG, a-2-microglobulin, digitoxin, HBe, anti-HBe, HBeAg, HIV 1/2gO, HIV Ag/Ab combo, testosterone, SCC, vitamin B12, folate, syphilis, anti-HBc, rubella IgG, rubella IgM, homocysteine, MPO, cytomegalovirus (CMV) IgG Avidity, toxo IgG avidity, toxo IgG, toxo IgM, C-peptide, vitamin D, HTLV I/II, total ahCG, progesterone, estradrogen, prolactin, myoglobin, tPSA, fPSA, carbamazepine (CBZ), digoxin, gentamicin, NAPA, phenytoin, phenobarbital, valproic acid, vancomycin, procaine, quinidine, tobramycin, methamphetamine (METH), amphetamine (AMPH), barbiturates, benzodiazepine, cannabis, cocaine, methadone, opiates, PCP, acetaminophen, ethanol, salicylates, tricyclics, holoTc, anti-CCP, HbA1c, barbs-U and modified fragments thereof. 15. The method of claim 1, wherein the signaling moiety is selected from the group consisting of a radiolabel, an enzyme, a chromophore, a flurophore, a chemiluminescent species, an ionophore and an electroactive species. 16. The method of claim 1, wherein detecting the signaling moiety comprises a technique selected from the group consisting of microscopy, reflectance measurement, optical density measurement, electrochemical detection, optical resonance, nuclear magnetic resonance (NMR), piezoelectric detection, pyroelectric detection, fluorescence detection, chemiluminescence or surface acoustic wave analysis. 17. The method of claim 1, wherein the oscillating step increases in frequency as the beads are forced to move back and forth across the electrode surface. 18. The method of claim 1, wherein the electrode is microfabricated. 19. The method of claim 1, wherein the electrode is amperometric. 20. The method of claim 1, wherein the electrode is a gold microarray. 21. The method of claim 1, wherein the washing of the immunosensor is performed with a wash fluid applied as at least one meniscus. 22. The method of claim 1, further comprising the step of mixing one or more differently-labeled magnetically susceptible beads into the sample. 23. The method of claim 1, performed by a system comprising a reader and a single-use cartridge containing the immunosensor.

Details for Patent 10,048,258

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974		2036-03-31
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984		2036-03-31
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985		2036-03-31
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990		2036-03-31